Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that it is discontinuing the development of odanacatib,
Mercks investigational cathepsin K inhibitor for osteoporosis, and will
not seek regulatory approval for its use.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orInvestors:Teri Loxam, 908-740-1986
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more